Investor Chernett now holds 13.9% of Neuronetics
Neuronetics, Inc. (STIM) discloses that investor Jorey Chernett has updated his Schedule 13D filing in Amendment No. 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neuronetics, Inc. (STIM) discloses that investor Jorey Chernett has updated his Schedule 13D filing in Amendment No. 4. The amendment primarily reflects a revised ownership percentage resulting from a change in Neuronetics’ outstanding common shares as reported in its August 11, 2026 Form 10-Q.
As of August 5, 2026, Neuronetics had 76,197,222 common shares outstanding, and Chernett beneficially owned 10,602,988 shares, representing approximately 13.92% of the company’s common stock. The filing states that these shares were acquired using personal funds for an aggregate purchase price of approximately $20,726,476. Chernett reports sole voting and dispositive power over the 10,602,988 shares and no shared power. Additional transaction details since the prior amendment are referenced in an exhibit.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13D regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Neuronetics (STIM) does Jorey Chernett own according to this Schedule 13D/A?
Why was Amendment No. 4 to the Schedule 13D for Neuronetics (STIM) filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.